Bevacizumab plus chemotherapy may leads to lower overall survival compared with chemotherapy (low certainty).
Hypofractionated radiotherapy showed no clear difference in overall survival compared with conventional radiotherapy (moderate certainty).
The review found no eligible studies for this question.
Hyperfractionated radiotherapy showed no clear difference in overall survival compared with conventional radiotherapy (low certainty).
Surgery plus endocrine therapy showed no clear difference in survival ‐ overall compared with primary endocrine therapy (low certainty).
It is very uncertain whether extended‐field chemoradiotherapy changes overall survival compared with pelvic chemoradiotherapy (very low certainty).
Biochemotherapy showed no clear difference in overall survival† compared with chemotherapy (high certainty).
Chemotherapy probably leads to lower overall survival compared with placebo, best supportive care (BSC) or no treatment (moderate certainty).
Chemotherapy probably leads to lower overall survival compared with best supportive care (moderate certainty).
Chemotherapy probably leads to lower overall survival compared with best supportive care (moderate certainty).
Polychemotherapy showed no clear difference in overall survival† compared with chemotherapy (high certainty).
Non‐steroidal antiandrogen monotherapy probably leads to higher overall survival compared with LHRH agonists or surgical castration monotherapy (moderate certainty).
The review found no eligible studies for this question.
High‐dose chemotherapy showed no clear difference in overall survival at 5‐year compared with chemotherapy without bone marrow transplant or stem cell rescue (high certainty).
Chemmotherapy combined with biological therapy showed no clear difference in overall survival compared with chemotherapy (moderate certainty).
It is very uncertain whether combination chemotherapy changes overall survival (3 years) compared with single‐agent chemotherapy (very low certainty).
Apatinib plus chemotherapy or chemotherapy/brachytherapy showed no clear difference in overall survival compared with chemotherapy or chemotherapy/brachytherapy (low certainty).
Neoadjuvant chemotherapy prior to interval surgery (NACT) showed no clear difference in overall survival ( compared with surgery followed by chemotherapy (PDS) (high certainty).
Summary of findings: Molecular‐targeted therapy plus chemotherapy showed no clear difference in overall survival compared with chemotherapy alone (low certainty).
The review found no eligible studies for this question.